LACTOLOGY FOUNDATION

This monograph summarizes toxicological and lactational safety aspects of meclozine-containing medicines in ATC class A04AB04 for use by healthcare professionals on a web-based reference page.medpedia.framar+1

ATC class A04AB04 overview

ATC A04AB04 comprises antihistaminic antiemetics based on meclozine (also spelled meclozine), a piperazine‑derivative H1 receptor antagonist.drugbank+1
Medicinal products in this class are indicated mainly for prevention and treatment of nausea, vomiting, motion sickness–related symptoms, and vertigo of vestibular origin.wikipedia+2

Active substance and pharmacological class

Meclozine is a first‑generation histamine H1 receptor antagonist with antiemetic and antivertigo properties and additional anticholinergic and central nervous system (CNS) depressant effects.medpedia.framar+1
Within ATC A04AB, it is categorized as an antihistamine antiemetic and belongs structurally to the group of piperazine derivatives.mims+2

Indications and clinical use

Meclozine is used for prophylaxis and treatment of nausea and vomiting, including motion sickness, and for symptomatic control of dizziness and vertigo associated with vestibular system disorders.drugbank+1
It may also be employed in other clinical contexts where nausea, vomiting, or vestibular imbalance are predominant symptoms, subject to national product labeling and regulatory approvals.mims+1

Mechanism of action

Meclozine exerts competitive antagonism at peripheral and central histamine H1 receptors, reducing histamine‑mediated signaling in the vestibular nuclei and vomiting center.drugbank
In addition, anticholinergic activity at muscarinic receptors contributes to suppression of labyrinthine responses and antiemetic effects, while CNS depressant and local anesthetic properties may further modulate symptom perception.medpedia.framar+1

Pharmacodynamics relevant to toxicity

Histamine H1 antagonism leads to decreased smooth muscle activation in the gastrointestinal tract, correlating with reduced emetic responses.medpedia.framar
Anticholinergic and CNS depressant actions explain common dose‑dependent adverse effects such as sedation, dry mouth, constipation, urinary retention, and dizziness, which are central to toxicological risk assessment.drugbank+1

Pharmacokinetics and exposure

Meclozine is administered orally, typically as tablets, with absorption leading to systemic distribution and passage into CNS structures involved in vestibular regulation.medpedia.framar+1
Detailed human data on elimination half‑life and transfer into breast milk are limited; regulatory labeling and Lactation databases emphasize that presence in human milk has not been adequately quantified.ncbi.nlm.nih+2

Contraindications and precautions

Meclozine is contraindicated in patients with known hypersensitivity to meclozine or excipients, and in individuals with conditions where anticholinergic effects may aggravate disease, such as glaucoma and prostatic hypertrophy.medpedia.framar
Use during pregnancy is generally discouraged in the referenced national monograph, and caution is recommended in older adults or patients with comorbidities that increase susceptibility to CNS depression and anticholinergic toxicity.mothertobaby+1

Adverse effects and dose‑related toxicity

Common adverse reactions include dizziness, constipation, urinary retention, and dry mouth, reflecting its antihistaminic and anticholinergic profile.drugbank+1
At higher exposures or in susceptible patients, excessive sedation, confusion, blurred vision, and exacerbation of narrow‑angle glaucoma or obstructive uropathy may occur, necessitating dose adjustment or discontinuation.droracle+1

Overdose and acute toxicity

Although detailed human overdose series are limited, toxicological expectations mirror those of other sedating H1 antihistamines, with pronounced CNS depression, anticholinergic manifestations (tachycardia, mydriasis, agitation), and potential respiratory compromise at extreme doses.aneskey+1
Supportive care in overdose focuses on airway protection, cardiovascular monitoring, management of anticholinergic symptoms, and avoidance of additional CNS depressants, particularly in pediatric and frail populations.aneskey

Drug interactions with toxicological relevance

Co‑administration with alcohol, benzodiazepines, opioids, or other CNS depressants may potentiate sedation and psychomotor impairment, increasing risk of falls and accidents.droracle+1
Combination with other anticholinergic agents (e.g., tricyclic antidepressants, antipsychotics, antiparkinsonian drugs) can enhance anticholinergic burden, predisposing to urinary retention, constipation, and delirium, especially in older adults.aneskey

General principles of lactational risk assessment

Virtually all orally administered medicines reach breast milk to some degree, but most do so in low concentrations that are unlikely to harm healthy term infants.mayoclinic+1
Lactational risk assessment for meclozine must balance maternal clinical need, infant age and health status, potential for sedation or feeding difficulties, and any theoretical impact on milk production.healthdirect+1

Meclozine and transfer into breast milk

Current data do not provide direct measurements of meclozine concentrations in human breast milk; regulatory information states that presence, infant effects, and impact on milk production have not been established.droracle+1
Because meclozine is lipophilic and protein‑bound with CNS activity, theoretical transfer into milk and infant exposure are considered possible, though likely limited at standard intermittent doses.droracle+1

Infant exposure and potential effects

Toxicologically, sedating antihistamines can cause infant drowsiness, poor feeding, and, rarely, respiratory depression if significant exposure occurs, although robust case data for meclozine are lacking.europeanjournalofmidwifery+1
Given meclozine’s CNS depressant and anticholinergic profile, clinical monitoring of breastfed infants for sedation, feeding difficulties, irritability, and changes in arousal is advised when maternal therapy is necessary.ncbi.nlm.nih+1

Effects on lactation and milk supply

Antihistamines with anticholinergic activity may theoretically reduce serum prolactin and interfere with lactation, with greater concern at high doses, chronic use, or when combined with other prolactin‑suppressing agents.mothertobaby+1
Available human data are sparse, but expert sources note that prolonged or high‑dose use of sedating antihistamines, including meclozine, may decrease milk supply in some women, particularly in the early postpartum period.ncbi.nlm.nih+1

Risk classification and expert consensus

Specialized lactation resources state that meclizine is probably acceptable during breastfeeding at usual doses, particularly for short‑term treatment, while acknowledging lack of direct milk concentration studies.droracle+1
Other expert commentaries suggest meclozine as a preferred choice over dimenhydrinate when an antihistamine antiemetic is required in lactation because dimenhydrinate has documented excretion into breast milk and potentially higher infant risk.droracle

Clinical use in breastfeeding women

When meclozine is clinically indicated for a breastfeeding mother, using the lowest effective dose for the shortest possible duration minimizes infant exposure and toxicological risk.droracle+1
Timing doses immediately after breastfeeding or before the infant’s longest sleep interval can further reduce peak drug levels in milk at subsequent feeds, an approach commonly recommended for medicines with sedative properties.infantrisk+1

Situations to avoid or use alternatives

In premature, low‑birth‑weight, or medically unstable infants, or when the infant already displays CNS depression or feeding problems, non‑pharmacological measures and lactation‑compatible alternatives to sedating antihistamines should be prioritized.healthdirect+1
Where repeated or high‑dose antiemetic therapy is anticipated, clinicians may consider agents with more robust lactation safety data and lower sedative burden, based on local guidelines and specialist advice.ncbi.nlm.nih+1

Summary of toxicological–lactological profile

For ATC A04AB04 meclozine‑based medicines, toxicological risk centers on dose‑dependent CNS depression and anticholinergic effects, which are generally manageable at standard doses but can be significant in overdose or vulnerable patients.drugbank+1
In lactation, limited direct data and theoretical concerns about infant sedation and reduced milk supply argue for cautious, time‑limited use, with meclozine often regarded as compatible when necessary, provided infants are monitored and alternative strategies considered in high‑risk dyads.ncbi.nlm.nih+2